权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Baptist Memorial Health Care/Mid South NCORP Minority Underserved Consortium

浸信会纪念医疗保健/中南 NCORP 服务不足的少数民族联盟

基本信息

批准号：
10670312
负责人：
Raymond U Osarogiagbon
金额：
$ 115.52万
依托单位：
BAPTIST MEMORIAL HOSPITAL - TIPTON
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-08-01 至 2025-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10670312
关键词：
Acceleration Achievement Active Sites Ambulatory Care American College of Radiology Imaging Network Arkansas Authorization documentation Baptist Church Breast Cancer Control Cancer Patient Cancer Therapy Evaluation Program Caring Catchment Area Chest Clinic Clinical Oncology Clinical Trials Community Health Community Healthcare County Data Development Disease Eastern Cooperative Oncology Group Enrollment Faith Foundations Funding Genitourinary system Goals Gynecologic Oncology Health Health Service Area Healthcare Healthcare Systems Heel Hematology Hospitals Indigent Individual Infrastructure Infusion procedures Institution Link Malignant Neoplasms Malignant neoplasm of thorax Medicaid Minority Groups Mission Mississippi Oncologist Oncology Outpatients Pathology Patient Care Patient Recruitments Patients Persons Population Prevention Private Practice Protocols documentation Provider Public Health Quality of Care Race Radiation Recruitment Activity Research Research Infrastructure Research Personnel Resources Rural Population Science Site Southwest Oncology Group System Tennessee Underinsured Underserved Population Uninsured anticancer research authority base cancer care cancer prevention care delivery electronic health record system forest gastrointestinal health disparity improved inpatient service member multidisciplinary participant enrollment programs racial minority racial population rural area social health determinants socioeconomics success underserved minority

项目摘要

The Baptist Memorial Health Care/Mid-South Minority Underserved NCORP is part of Baptist Memorial Healthcare Corporation (BMHCC), a non-for-profit faith-based healthcare system with 22 hospitals, 21 outpatient oncology clinics, 8 radiation facilities, and 19 outpatient infusion centers, providing care for approximately 8000 new cancer patients each year. BMHCC’s service area covers 111 counties, 4.3 million people. This is 44% of the 252 counties and parishes in the Delta Regional Authority, congressionally acknowledged as the most indigent population in the US. BMHCC provides 25% of cancer care in this racially, socioeconomically and culturally diverse region, which has some of the highest volumes of cancer and the most fragile public health infrastructure in the US. Before our NCORP, these patients had no access to clinical trials. In the 4 years since our NCORP began in August 2014, more than 90 patients per year have been enrolled into trials, including 168 patients in 2017/18; 39% of our enrolled patients are racial minorities, 17% reside in rural areas, 13% are uninsured, 21% have Medicaid. Members of our NCORP serve on multiple NCORP taskforces and NCI Steering Committees, including the Cancer Prevention Steering Committee. We have used our unique expertise in establishing Multidisciplinary Care Delivery programs in Breast, Thoracic, Gastrointestinal and Hematologic Oncology to develop Disease-Specific Research Groups that link our NCORP research closely to our clinical oncology care programs. This strategy has accelerated our progress in the past 2 years. Our system-wide implementation of the Electronic Health Record system, EPIC, has enhanced our research ability, especially in Cancer Care Delivery Research. For the new funding cycle, we propose to expand our NCORP research infrastructure across the full extent of BMHCC, with special emphasis on increasing patient recruitment across the state of Mississippi. Using Implementation and Team Science principles and a data-driven approach, our overarching goal is to increase the proportion of BMHCC oncology patients who participate in clinical trials from <3% in 2018 to 10% by 2025. With almost 8000 annual new cancer cases, this would significantly exceed the minimum requirements of the NCORP, to the benefit of our patients, communities and healthcare system, because we believe that ‘the best treatment is a clinical trial.’ Our specific aims are to increase the: 1.) number of active sites from 5 to 16 by 2025, by expanding to all our Mississippi institutions; 2.) proportion of oncology-related providers accruing patients to >90%; 3.) clinical trials activity in urogenital and gynecologic oncology; 4.) average annual patient-enrollment into NCORP trials from 90 to >250. Achieving our goal will help achieve the NCI’s mission of improving the health of this key US population demographic by narrowing a major recognized health disparity: poor access of the large indigent, racial minority and rural populations within the Mississippi Delta region to high quality oncologic care.

浸信会纪念医疗保健/中南部少数民族服务不足NCORP是浸信会纪念的一部分

项目成果

期刊论文数量（9）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

The Anatomy and Physiology of Teaming in Cancer Care Delivery: A Conceptual Framework.

癌症护理中团队合作的解剖学和生理学：概念框架。

DOI：
10.1093/jnci/djaa166
发表时间：
2021
期刊：
Journal of the National Cancer Institute
影响因子：
0
作者：
Verhoeven,DanaC;Chollette,Veronica;Lazzara,ElizabethH;Shuffler,MarissaL;Osarogiagbon,RaymondU;Weaver,SallieJ
通讯作者：
Weaver,SallieJ

Interest in Cessation Treatment Among People Who Smoke in a Community-Based Multidisciplinary Thoracic Oncology Program.

DOI：
10.1016/j.jtocrr.2021.100182
发表时间：
2021-06
期刊：
JTO clinical and research reports
影响因子：
0
作者：
Meadows-Taylor M;Ward KD;Chen W;Faris NR;Fehnel C;Ray MA;Ariganjoye F;Berryman C;Houston-Harris C;McHugh LM;Pacheco A;Osarogiagbon RU
通讯作者：
Osarogiagbon RU

The future in the instant: The lung adenocarcinoma classification as a predictor of future adverse events.

未来即刻：肺腺癌分类作为未来不良事件的预测因子。

DOI：
10.1016/j.lungcan.2021.03.010
发表时间：
2021
期刊：
Lung cancer (Amsterdam, Netherlands)
影响因子：
0
作者：
Osarogiagbon,RaymondU
通讯作者：
Osarogiagbon,RaymondU

Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best-practice guide.

获取用于晚期肺癌诊断和综合生物标志物测试的组织：国家肺癌圆桌会议最佳实践指南。

DOI：
10.3322/caac.21774
发表时间：
2023
期刊：
CA: a cancer journal for clinicians
影响因子：
0
作者：
Fox,AdamH;Nishino,Mizuki;Osarogiagbon,RaymondU;Rivera,MPatricia;Rosenthal,LaurenS;Smith,RobertA;Farjah,Farhood;Sholl,LynetteM;Silvestri,GerardA;Johnson,BruceE
通讯作者：
Johnson,BruceE

The Pathologic Nodal Staging Quality Gap: Challenge as Opportunity in Disguise.

病理淋巴结分期质量差距：挑战是变相的机遇。